Medical Oddities: Dogs share our mortality markers
-
By
-
Teraya Smith
-
September 2, 2026
-
5 min
By
Teraya Smith
September 2, 2026
Five reproducible MASLD subtypes showed distinct genetic profiles and patterns of metabolic comorbidity and disease progression.
September 10, 2026
Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.
August 25, 2026
The accelerated approval adds an immunotherapy option for patients with MSI-H/dMMR stage II/III disease.
by Mouj Hijazi
October 19, 2026